AURORA CANNABIS INC

Curaleaf’s $4.00‑per‑share bid offers Aurora Cannabis a 45% premium, sparking a 20% rally and prompting a strategic review amid cannabis industry consolidation.

Explore Aurora Cannabis Inc.’s fragile rise: regulatory hurdles, negative P/E, and a high‑risk profile amid a consolidating medical‑cannabis market.

Aurora Cannabis Inc. has released its fiscal 2025 fourth-quarter earnings, with analysts projecting a significant improvement in earnings per share from the previous year.

Aurora Cannabis Inc. is well-positioned to capitalize on the rapidly expanding global cannabidiol market, which is projected to reach USD 22.05 billion by 2030.

Aurora Cannabis Inc. is well-positioned to capitalize on the rapidly expanding global cannabidiol market, which is projected to reach USD 22.05 billion by 2030.